Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients After FDA Reverses Course

 
• By Mandy Jackson
  
The FDA recommended removing a voluntary hold on shipments of Elevidys to ambulatory DMD patients (Shutterstock)

More from Drug Safety

More from Pink Sheet